BioNxt Solutions Inc. (CVE:BNXT) | Finanzwire

Basculer en Français

10855	Companies
235900	Keywords
164845	Articles
126462	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 08/19/2026 at 09:10, 22 hours 2 minutes ago

BioNxt Completes IMPD for Multiple Sclerosis Treatment

Clinical Trials Multiple Sclerosis BioNxt Solutions Drug Delivery Systems IMPD Completion
PRESS RELEASE

published on 08/19/2026 at 09:05, 22 hours 7 minutes ago

BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
BioNxt Solutions Inc. completes Investigational Medicinal Product Dossier (IMPD) for BNT23001, a sublingual cladribine oral dissolvable film for multiple sclerosis. IMPD is a significant regulatory milestone for the Company's lead drug candidate

BioNxt Solutions Inc. Sublingual Cladribine BNT23001 Investigational Medicinal Product Dossier IMPD
BRIEF

published on 08/17/2026 at 12:45, 2 days 18 hours ago

BioNxt Provides Update on Sublingual Drug Delivery Pipeline

Intellectual Property Cladribine Program Pharmaceutical Innovation BioNxt Solutions Sublingual Drug Delivery
PRESS RELEASE

published on 08/17/2026 at 12:40, 2 days 18 hours ago

BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
BioNxt Solutions Inc. provides update on proprietary sublingual thin-film drug delivery pipeline including Cladribine for multiple sclerosis, autoimmune disease expansion, Everolimus, and Semaglutide

BioNxt Solutions Inc. Intellectual Property Autoimmune Diseases Cladribine Sublingual Thin-film Drug Delivery
BRIEF

published on 08/04/2026 at 09:10, 15 days 22 hours ago

BioNxt Solutions Updates on Sublingual Drug Delivery Progress

Intellectual Property Pharmaceutical Innovation Sublingual Drug Delivery Cladribine Development Everolimus And Semaglutide
PRESS RELEASE

published on 08/04/2026 at 09:05, 15 days 22 hours ago

BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
BioNxt Solutions Inc. provides update on proprietary drug delivery pipeline focusing on Cladribine for MS, autoimmune diseases, Everolimus, Semaglutide. Strengthening IP portfolio

BioNxt Solutions Inc. Intellectual Property Autoimmune Diseases Cladribine Drug Delivery Pipeline
BRIEF

published on 08/01/2026 at 00:30, 19 days 6 hours ago

BioNxt Solutions Issues New Stock Options

Stock Options Canadian Securities Exchange Vesting BioNxt Solutions Option Plan
PRESS RELEASE

published on 08/01/2026 at 00:25, 19 days 6 hours ago

BioNxt Solutions Announces Option Grants
BioNxt Solutions Inc. announces stock options grants under Option Plan to insiders, consultants, and employees. Focus on drug delivery innovations and cancer treatment platforms

Stock Options Cancer Treatment Innovations BioNxt Solutions Inc. Drug Delivery
BRIEF

published on 07/06/2026 at 09:10, 1 month 13 days ago

BioNxt Progresses with Sublingual Semaglutide ODF Development

Drug Delivery Pharmaceutical Development BioNxt Solutions Sublingual ODF GLP-1 Therapeutics
PRESS RELEASE

published on 07/06/2026 at 09:05, 1 month 13 days ago

BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
BioNxt Solutions Inc. announces progress in Semaglutide oral dissolvable film program for GLP-1 therapies, expanding into a rapidly growing pharmaceutical market

BioNxt Solutions Inc. Pharmaceutical Market Oral Dissolvable Film GLP-1 Therapies Semaglutide

Accesswire

Published on 08/20/2026 at 02:22, 4 hours 50 minutes ago

Infrastructure Sterilisation Drilling Begins at Tunkillia
Published on 08/20/2026 at 01:00, 6 hours 12 minutes ago

Irving Resources Announces Results of AGM
Published on 08/20/2026 at 00:40, 6 hours 32 minutes ago

Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program
Published on 08/19/2026 at 22:00, 9 hours 12 minutes ago

Jaguar Health Reports Second Quarter 2026 Financials
Published on 08/19/2026 at 20:35, 10 hours 37 minutes ago

Revive Therapeutics Announces Proposed Shares for Debt Settlement

View all ACCESSWIRE

EQS Group

Published on 08/20/2026 at 07:00, 12 minutes ago

1H26: Swiss Prime Site delivers a strong operating result and sustained growth; FFO I of CHF 2.15 per share (+2.4%)
Published on 08/20/2026 at 07:00, 12 minutes ago

Centiel reports strong 2026 Half-Year results and invests into future growth
Published on 08/20/2026 at 07:00, 12 minutes ago

New upcycle: SBO bookings increase in H1 despite Middle East conflict
Published on 08/20/2026 at 07:00, 12 minutes ago

NFON advances its strategic transformation in a challenging environment
Published on 08/20/2026 at 06:30, 42 minutes ago

Pleasing operating result in first half of 2026

Les Echos

Published on 08/18/2026 at 11:15, 1 day 19 hours ago

GUILLEMOT CORPORATION | Weekly report share buyback from August 10 to August 14 2026
Published on 08/17/2026 at 19:45, 2 days 11 hours ago

Aéroports de Paris S.A - July 2026 traffic figures
Published on 08/17/2026 at 17:45, 2 days 13 hours ago

Weekly share buyback
Published on 08/17/2026 at 08:33, 2 days 22 hours ago

Covivio - Information on Treasury shares transactions between August 10th, 2026 and August 11th, 2026
Published on 08/17/2026 at 07:30, 2 days 23 hours ago

Disclosure of transactions in own shares from August 10 to August 14, 2026

View all LES ECHOS COMFI WIRE